Document Detail

Mineralocorticoid receptor antagonists for heart failure.
MedLine Citation:
PMID:  22082128     Owner:  NLM     Status:  MEDLINE    
INTRODUCTION: Although mineralocorticoid receptor (MR) antagonists are indicated in systolic heart failure, they are underprescribed in patients with appropriate indications for their prescription and often used in those in whom the evidence for probable benefit is scant. The rate of adverse events in practice has exceeded that foreshadowed by randomized controlled trials (RCTs). With the recent publication of the landmark therapeutic trial (EMPHASIS), it is timely to review the appropriate use of these agents in heart failure.
AREAS COVERED: This review addresses the pathophysiological importance of MR activation in heart failure and summarizes pivotal RCTs of MR antagonists in heart failure.
EXPERT OPINION: MR antagonism reduces mortality and morbidity in heart failure with reduced systolic function in severe chronic disease, in heart failure complicating myocardial infarction and also in those with impaired systolic function (but only mild symptoms). Evidence for benefits in a significant proportion of 'real-life' patients with heart failure, including those with preserved left ventricular ejection fraction, is lacking. MR antagonism is an important part of the pharmaceutical armamentarium in managing heart failure but must be prescribed with careful case selection, taking note of the evidence of where risks are acceptable and benefits are likely.
Arthur Mark Richards
Related Documents :
16010688 - Radiofrequency perforation and conventional needle percutaneous transseptal left heart ...
1753158 - Limitations in the use of five french coronary catheters.
594558 - Detection of a temporary cardiac pacing catheter in the left ventricle by chest x-ray.
6693628 - Surgical correction of the wolff-parkinson-white syndrome in the closed heart using cry...
15735848 - Off pump coronary artery bypass graft surgery versus conventional coronary artery bypas...
12559528 - Oral loading single dose flecainide for pharmacological cardioversion of recent-onset a...
Publication Detail:
Type:  Journal Article; Review     Date:  2011-11-14
Journal Detail:
Title:  Expert opinion on pharmacotherapy     Volume:  12     ISSN:  1744-7666     ISO Abbreviation:  Expert Opin Pharmacother     Publication Date:  2011 Dec 
Date Detail:
Created Date:  2011-11-21     Completed Date:  2012-04-16     Revised Date:  2013-11-25    
Medline Journal Info:
Nlm Unique ID:  100897346     Medline TA:  Expert Opin Pharmacother     Country:  England    
Other Details:
Languages:  eng     Pagination:  2801-15     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Aldosterone / metabolism*
Heart Failure / drug therapy*,  metabolism*,  mortality
Mineralocorticoid Receptor Antagonists* / administration & dosage,  adverse effects,  therapeutic use*
Randomized Controlled Trials as Topic
Spironolactone / administration & dosage,  adverse effects,  analogs & derivatives*,  therapeutic use
Treatment Outcome
Reg. No./Substance:
0/Mineralocorticoid Receptor Antagonists; 27O7W4T232/Spironolactone; 4964P6T9RB/Aldosterone; 6995V82D0B/eplerenone
Comment In:
Expert Opin Pharmacother. 2011 Dec;12(18):2767-9   [PMID:  22098225 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Th17-related cytokines: new players in the control of chronic intestinal inflammation.
Next Document:  Intracranial Angioplasty and Stenting Through Direct Carotid Puncture.